Details
Description
Inclusion Criteria
Exclusion Criteria
Details
Title Clinical predictors of benefit from pemetrexed in patients with metastatic non small cell lung cancer
IRB CHRV 0090
Hospital Main Campus
Stage N/A
Phase N/A
Disease Lung
Drug Pemetrexed
Description
Primary- The primary goal of this study is to identify clinical and pathologic characteristics associated with extended progression-free survival in patients with metastatic NSCLC patients treated with pemetrexed.
- Secondary goals are to examine factors associated with objective response and pemetrexed-related toxicity
Inclusion Criteria
- Patients must have a proven diagnosis of metastatic NSCLC
- Documented treatment with pemetrexed in the metastatic setting
Exclusion Criteria
- Patients who have received pemetrexed as part of definitive concurrent chemoradiation for locally advanced NSCLC, or as adjuvant treatment after resection for early stage NSCLC